A5092163943- Vector-borne infectious diseases
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Digital Imaging for Blood Diseases
- vaccines and immunoinformatics approaches
- Insect and Pesticide Research
- Machine Learning in Bioinformatics
University of California, Los Angeles
2023-2024
Point-of-care serological and direct antigen testing offers actionable insights for diagnosing challenging illnesses, empowering distributed health systems. Here, we report a POC-compatible serologic test Lyme disease (LD), leveraging synthetic peptides specific to LD antibodies paper-based platform rapid, cost-effective diagnosis. Antigenic epitopes conserved across Borrelia burgdorferi genospecies, targeted by IgG IgM antibodies, are selected develop multiplexed panel detection of from...
Abstract Point-of-care (POC) serological testing provides actionable information for several difficult to diagnose illnesses, empowering distributed health systems. Accessible and adaptable diagnostic platforms that can assay the repertoire of antibodies formed against pathogens are essential drive early detection improve patient outcomes. Here, we report a POC serologic test Lyme disease (LD), leveraging synthetic peptides tuned be highly specific LD antibody across patients compatible with...
Lyme disease (LD) is a tick-borne illness and can lead to severe health complications if left undiagnosed/untreated. This study introduces novel approach point-of-care testing for LD, utilizing deep-learning-enabled peptide-based serodiagnosis. 82 unique patient serum samples were used validation, obtained from the Bay Area Disease Biobank CDC Serum Repository. Blinded test results demonstrated outstanding diagnostic performance, with 84.0% sensitivity 96.3% specificity. By integrating deep...
Lyme disease (LD) is a tick-borne illness caused by the bacterium Borrelia burgdorferi, which can cause severe symptoms if untreated. We present novel diagnostic platform utilizing synthetic peptides and deep-learning-based analytical algorithm to detect LD-specific antibodies in patient serum samples. Blinded samples acquired from Centers for Disease Control Prevention (CDC) were tested using our platform, achieving sensitivity of 95% among disseminated specificity 100% across all healthy...